Elekta inks oncology co-selling deal with IBM Watson Health

Elekta (STO:EKTA B) said today it inked a collaborative sales deal with IBM‘s (NYSE:IBM) Watson Health through which Elekta will offer IBM’s Watson for Oncology with its cancer care solutions.

With the deal, Elekta said it will begin offering the Watson for Oncology early this year as a clinical decision support solution paired with its digital cancer care solutions, including the Mosaiq oncology information systems.

The combined offerings will be made available in markets including the US, Brazil, India, Australia and select European and Asian markets, Elekta said.

“Joining forces with IBM Watson Health positions Elekta as the first radiation therapy company to offer capabilities that combine conventional health information systems with artificial intelligence and cognitive cloud computing. Our goal is to bring cutting edge artificial intelligence technology to the cancer care continuum, including treatment planning, enabling evidence-based treatment recommendations for every patient regardless of where they are treated. We are excited to be working with IBM Watson Health to achieve this shared vision,” Elekta CEO Richard Hausmann said in a press release.

“Oncologists around the world rely on Mosaiq to support the treatment pathway, and we are eager to extend Watson for Oncology to more physicians and patients globally through Elekta’s sophisticated digital oncology solutions. We are proud to bring the evidence based clinical decision support of Watson for Oncology together with Elekta’s extensive expertise in the oncology EHR and radiation therapy field,” IBM Watson Health oncology & life sciences VP Lisa Rometty said in prepared remarks.

Last month, Elekta said it inked an exclusive deal with Brainlab to make it the authorized distributor of Elekta’s stereotactic neurosurgery solutions.

The post Elekta inks oncology co-selling deal with IBM Watson Health appeared first on MassDevice.

from MassDevice http://ift.tt/2GBx1x9